MILBETAB 12,5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Authorised

- Milbemycin oxime
- Praziquantel

Product identification

Medicine name:
MILBETAB 12,5 MG/125 MG CHEWABLE TABLETS FOR DOGS

Active substance:
Milbemycin oxime

Praziquantel

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Milbemycin oxime
12.50 milligram(s) / 1.00 Tablet

Praziquantel

125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Italy

Package description:
1 box with 1 blister of 2 chewable tablets
Box with 2 blister strips of 2 chewable tablets
Box with 1 blister strips of 5 chewable tablets
Box with 5 blisters strips of 2 chewable tablets
Box with of 6 blister strips of 2 chewable tablets
Box with 3 blister strips of 5 chewable tablets
Box with 10 blisters strips of 2 chewable tablets
Box with 12 blister strips of 2 chewable tablets
Box with 5 blister strips of 5 chewable tablets,
Box with 6 blister strips of 5 chewable tablets
Box with 7 blister strips of 5 chewable tablets
Box with 8 blister strips of 5 chewable tablets
Box with 9 blister strips of 5 chewable tablets
Box with 24 blisters strips of 2 chewable tablets
Box with 10 blister strips of 5 chewable tablets
Box with 1 blister strip of 4 chewable tablets
Box with 2 blister strip of of 5 chewable tablets
Box with of 3 blisters strips of 4 chewable tablets
Box with 5 blister strips of 4 chewable tablets
Box with 6 blisters strips of 4 chewable tablets
Box with 12 blister strips of 4 chewable tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:
19/12/2025

Manufacturing sites for batch release:
Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:
European Medicines Agency

Authorisation number:
105825

Date of authorisation status change:
19/12/2024

Reference member state:
France

Procedure number:
FR/V/0488/001

Concerned member states:
Austria Belgium Czechia Finland Germany Hungary Ireland Italy Netherlands Norway Poland Portugal Spain Sweden

Generic of:
600000043292

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.